{
  "ptid_time": "016_S_5031_2013-02-13",
  "img_path": "/data/qiuhui/data/adni/images/016_S_5031/2013-02-13/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 73,079 mm³, 97.7% above the reference mean. With a Z-score of 2.64 (99.6th percentile), this represents significant enlargement; hippocampal volume measures 5,040 mm³, 22.4% below the reference mean. With a Z-score of -1.80 (3.6th percentile), this represents moderate atrophy; whole brain volume measures 908,134 mm³, 2.2% below the reference mean. With a Z-score of -0.26 (39.8th percentile), this represents normal volume ; entorhinal cortex volume measures 2,147 mm³, 38.0% below the reference mean. With a Z-score of -2.05 (2.0th percentile), this represents significant atrophy; fusiform gyrus volume measures 16,328 mm³, 1.4% above the reference mean. With a Z-score of 0.10 (54.1th percentile), this represents normal volume ; middle temporal gyrus volume measures 19,032 mm³, 5.6% above the reference mean. With a Z-score of 0.50 (69.0th percentile), this represents normal volume . ",
  "text_data": "Age is 80.2 years. Gender is Female. Education: 14 years. MMSE: 25.0. MoCA: 20.0. Logical Memory: 6.0. APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.52 SUVR (profound elevated); Amyloid beta: 635.60 pg/mL (mild reduced); Total tau: 191.10 pg/mL (normal ); Phosphorylated tau: 16.82 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The data shows significant ventricular enlargement (consistent with atrophy) and moderate-to-severe atrophy in the hippocampus and entorhinal cortex—key regions affected in Alzheimer's disease. The MMSE (25) and MoCA (20) scores suggest cognitive impairment, while AV45 (amyloid PET) shows profound elevation, supporting amyloid pathology. However, CSF biomarkers (Aβ mildly reduced, normal tau) are less typical of AD, and APOE4-negative status reduces genetic risk.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely amyloid-positive, with mixed neurodegenerative features).  \n**Confidence:** **Medium** (due to conflicting biomarker patterns—high amyloid PET but mild CSF Aβ reduction and normal tau).  \n\n*Note:* Progression to dementia is likely given the structural and amyloid findings, but current cognitive scores and tau levels don't yet meet dementia criteria. Follow-up clinical correlation is needed.",
  "timestamp": "2025-07-26T00:37:56.463660"
}